Pomegranate Compound Boosts Heart Function in HFpEF Models

What if a molecule made by your gut after eating pomegranate could loosen a stiff heart? Researchers at King's College London report that urolithin A, a metabolite produced when the body digests compounds in pomegranate, walnuts and some berries, dramatically improved heart function in laboratory models of a difficult-to-treat form of heart failure.

Heart failure with preserved ejection fraction, or HFpEF, is a tricky clinical problem. The heart pumps out blood normally, but the muscle becomes rigid and cannot relax enough between beats to fill properly. Patients struggle with breathlessness, fatigue and reduced exercise tolerance. HFpEF accounts for about half of all heart failure cases and currently has limited targeted treatments.

The new study tested urolithin A in animal models designed to mimic HFpEF. The compound improved indicators of cardiac performance by as much as 80 percent. It also reduced fibrosis, the process by which scar tissue builds up in the heart, and prevented abnormal enlargement of heart muscle cells that worsens function. Lab experiments showed treated heart tissue relaxed more fully between beats, a central defect in HFpEF.

How a gut-derived molecule nudges heart biology

The team identified a likely molecular route for these benefits. Urolithin A appears to activate a protein called PKG1α, which plays a role in blood vessel function and the ability of the cardiac muscle to relax. The compound modifies a particular amino acid on PKG1α and, through that change, turns on a pathway linked to improved relaxation and reduced fibrotic signaling.

To bridge the gap between animals and people, researchers also applied urolithin A to engineered human cardiac tissue grown from pluripotent stem cells. Those human tissue models showed a measurable improvement in relaxation after exposure to the compound, suggesting the mechanism seen in animals can operate in human cells as well.

Findings are published in Science Advances, with support from the British Heart Foundation. The authors caution that these results come from preclinical models and laboratory tissues; they do not amount to a clinical recommendation to use pomegranate or supplements as a treatment for HFpEF.

Still, the implications are intriguing. Could boosting urolithin A production through diet or by harnessing the gut microbiome reduce HFpEF symptoms? Or might pharmaceutical development produce safe, targeted drugs that mimic urolithin A's effect on PKG1α? Both paths are plausible but require careful clinical testing.

For now clinicians and patients should view the work as promising early-stage science. Randomized clinical trials are essential to determine whether the improvements seen in animals and engineered human tissue translate to measurable benefits in people with HFpEF. Until such trials are complete, this research adds an important piece to the puzzle of how metabolism, diet and molecular signaling intersect in cardiac disease.